Endothelial pannexin 1 channels control inflammation by regulating intracellular calcium

Yang Yang^{1,2}, Leon Delalio¹, Angela K Best¹, Edgar Macal¹, Jenna Milstein¹, Iona Donnelly³, Ashley M. Miller³, Martin McBride³, Xiaohong Shu², Michael Koval^{4,5}, Brant E. Isakson^{1,6*} and Scott R. Johnstone^{1*}

¹Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine

²Department of Pharmacology, Dalian Medical University, Dalian 116044, China

³British Heart Foundation Cardiovascular Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK

⁴Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA

⁵Department of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA

⁶Department of Molecular Physiology and Biophysics, University of Virginia School of Medicine

Running Title: Pannexin 1 in Inflammation

Manuscript Word Count:

Figures: 4 main figures + 3 supplemental figures

***Co-Corresponding Authors:**

Brant E. Isakson and Scott R. Johnstone

University of Virginia School of Medicine, 409 Lane Rd, MR4 Building; Rm 6071, Charlottesville, VA, 22901 E: srj6n@virginia.edu; brant@virginia.edu P:434-924-2093, F: 434-924-2828

Lead Contact

Scott R. Johnstone

University of Virginia School of Medicine, 409 Lane Rd, MR4 Building; Rm 6071, Charlottesville, VA, 22901 E: srj6n@virginia.edu P:434-924-2093, F: 434-924-2828

Keywords: Pannexin, Panx1, interleukin-1 β , NF κ β , ATP, calcium, gene regulation, channel, inflammation, endothelial cell, smooth muscle cell

In Brief

Interleukine-1 beta (IL-1 β) has been identified as a critical factor that contributes to the inflammatory response in cardiovascular disease (e.g., atherosclerosis). Pannexin 1 (Panx1) channel activity in endothelial cells regulates localized inflammatory cell recruitment. In response to prolonged tumor necrosis factor alpha (TNF) treatment, Yang et al. found that the Panx1 channel is targeted to the plasma membrane, where it facilitates an increase in intracellular calcium to control the production and release of cytokines including IL-1 β .

GRAPHICAL ABSTRACT

Abstract

The proinflammatory cytokine IL-1 β is a significant risk factor in cardiovascular disease that can be targeted to reduce major cardiovascular events. IL-1 β expression and release are tightly controlled by changes in intracellular Ca²⁺. In addition, purinergic signaling through ATP release has also been reported to promote IL-1 β production. Despite this, the mechanisms that control IL-1 β synthesis and expression have not been identified. The pannexin 1 (Panx1) channel has canonically been implicated in ATP release, especially during inflammation. However, resolution of purinergic signaling occurs quickly due to blood flow and the presence of ectonucleotidases. We examined Panx1 in human endothelial cells following treatment with the pro-inflammatory cytokine tumor necrosis alpha (TNF). In response to long-term TNF treatment, we identified a dramatic increase in Panx1 protein expression at the plasma membrane. Analysis by whole transcriptome sequencing (RNA-seq), qPCR, and treatment with specific kinase inhibitors, revealed that TNF signaling induced NF κ B-associated Panx1 transcription. Genetic inhibition of Panx1 reduced the expression and secretion of IL-1 β . We initially hypothesized that increased Panx1-mediated ATP release acted in a paracrine fashion to control cytokine expression. However, our data demonstrate that IL-1 β expression was not altered after direct ATP stimulation, following degradation of ATP by apyrase, or after pharmacological blockade of P2 receptors. These data suggest that non-purinergic pathways, involving Panx1, control IL-1 β production. Because Panx1 forms a large pore channel, we hypothesized it may act to passively diffuse Ca²⁺ into the cell upon opening to regulate IL-1 β . High-throughput flow cytometric analysis demonstrated that TNF treatments lead to elevated intracellular Ca²⁺. Genetic or pharmacological inhibition of Panx1 reduced TNF-associated increases in intracellular Ca²⁺, and IL-1 β transcription. Furthermore, we found that the Ca²⁺-sensitive NF κ B-p65 protein failed to localize to the nucleus after genetic or pharmacological block of Panx1. Taken together, our study provides the first evidence that intracellular Ca²⁺ regulation via the Panx1 channel induces a feed-forward effect on NF κ B to regulate IL-1 β synthesis and release in endothelium during inflammation.

INTRODUCTION

Sustained inflammatory responses critically regulate the pathogenesis of endothelial dysfunction and atherosclerosis (Libby and Hansson, 2015; Libby et al., 2013). The release of tumor necrosis factor alpha (TNF) enhances inflammation in atherosclerosis and TNF concentrations are associated with elevated risk of atherothrombosis and resulting major adverse cardiovascular events (Barath et al., 1990; Ridker, 2013; Ridker et al., 2000). While many studies have focused on the effect of TNF on inflammatory cells (Bradley, 2008), TNF has also been shown to induce production of pro-inflammatory cytokines in endothelial cells (ECs) (Imaizumi et al., 2000; Perrot-Applanat et al., 2011). In the presence of TNF, ECs synthesize and release pro-inflammatory cytokines and chemokines that enhance the inflammatory response, correlating with a high risk of vascular injury (Perrot-Applanat et al., 2011; Viemann et al., 2006). Targeting inflammation, e.g. using TNF antagonists, leads to reductions in cytokine expression by ECs and can reduce atherosclerotic lesion formation (Alexander et al., 2012; Di Minno et al., 2011; Gabay et al., 2016; Virone et al., 2019). Thus, defining critical EC signaling pathways may help identify therapeutic targets. Among these potential targets, interleukin-1 β (IL-1 β) is widely considered to be a highly active and essential regulator of the pathogenesis of human atherosclerotic disease progression and susceptibility to atherothrombosis (Ridker et al., 2012). Therapeutically targeting IL-1 β decreases its activity and is associated with a reduced expression of multiple pro-inflammatory cytokines, including interleukin-6 (IL-6), which have been implicated as a potential causal pathway for atherosclerotic events (Ridker et al., 2017; Solomon et al., 2018). In the recent Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS), IL-1 β neutralization by canakinumab reduced inflammation and reduced major adverse cardiovascular events associated with atherothrombosis in high-risk patients (Ridker et al., 2017; Ridker et al., 2012). While other pro-inflammatory cytokines such as IL-6 have been implicated in atherosclerosis, clinical trials targeting this did not result in marked improvements in patient risk, highlighting the importance of targeting specific pro-inflammatory markers (Ridker et al., 2019; Ridker et al., 2018). The efficacy of specific IL-1 β blockade in inflammation highlights the need to elucidate the molecular mechanisms that regulate its synthesis and release.

Adenosine triphosphate (ATP), is increasingly recognized as an important factor in the regulation of the inflammatory process, leading to activation of the inflammasome (Maitre et al., 2015; Mariathasan et al., 2006; Qu et al., 2011), and multiple studies have demonstrated its association with increases in IL-1 β synthesis and release (Kanjamekanant et al., 2013; Mehta et al., 2001). While some studies suggest that ATP alone is capable of increasing IL-1 β synthesis and release

(Kanjamekanant et al., 2013), a “two-signal” model of production followed by later activation has emerged for IL-1 β (Cullen et al., 2015; Mehta et al., 2001). In this model, ATP acts to enhance the magnitude and velocity of posttranslational processing of pro-IL-1 β , yielding the bioactive molecule, which is released into the extracellular space (Cullen et al., 2015). However, in this model, IL-1 β synthesis is not controlled via ATP, rather through pathways stimulated via pathogen-associated molecules such as LPS (Cullen et al., 2015; Stoffels et al., 2015). Release of ATP from cells can also signal locally through paracrine receptors (e.g. P2X7) to promote K⁺ release leading to uptake of extracellular Ca²⁺, which is associated with an increase in the expression and release of cytokines including IL-1 β (Jantarotnotai et al., 2009; Wilson et al., 2007; Yaron et al., 2015). Further data suggests that chelation of intracellular Ca²⁺ inhibits the processing and release of IL-1 β , suggesting that an influx of extracellular Ca²⁺ is also centrally linked to IL-1 β production (Ainscough et al., 2015; Brough et al., 2003). Despite this, the source and regulation of increased intracellular Ca²⁺ has not been rigorously defined (Ainscough et al., 2015; Brough et al., 2003).

Pannexin 1 (Pannx1) forms large, non-selective plasma membrane channels that permit the movement of molecules and ions, including ATP to the extracellular space and Ca²⁺ from ER (Chiu et al., 2018; Vanden Abeele et al., 2006). Pannx1 channels at the plasma membrane can facilitate multiple physiological and pathophysiological processes including vascular constriction, apoptosis, tumor cell metastasis, and neuronal communication (Billaud et al., 2011; Cheken et al., 2010; Orellana et al., 2011; Thompson et al., 2008). Recently, we identified that endothelial Pannx1 channel opening and ATP release promotes leukocyte recruitment (Lohman et al., 2015) that plays a fundamental role in inflammation and tissue damage within ischemic stroke (Good et al., 2018b). There is increasing evidence that blocking Pannx1 channels may control inflammasome activation, inflammatory cytokine release and inflammatory cell recruitment (Albalawi et al., 2017; Lappas, 2014; Pelegrin, 2008). However, the mechanisms underlying this response have not been described. This led us to hypothesize that Pannx1 signaling may be involved in the control of IL-1 β production and secretion by ECs. We report here that EC Pannx1 is a direct target of the TNF signaling pathway and demonstrate for the first time that Pannx1 channels facilitate the transport of extracellular Ca²⁺ to promote a feed forward effect on the synthesis of IL-1 β .

RESULTS

TNF induces Panx1 expression and membrane targeting of Panx1 channels in endothelial

cells. In human umbilical vein endothelial cells (HUVECs), we initially demonstrate that prolonged exposure to TNF (2.5ng/mL) for 5 hr and 24 hr leads to an increase in the transcription of Panx1, measured by qRT-PCR (**Figure 1A**). Increases in Panx1 mRNA levels correlate with significant increases in protein expression of Panx1 at 5 hr, measured by immunoblotting (**Figure 1B**). The multiple banding pattern for the Panx1 protein observed in immunoblots represents differential Panx1-glycosylation (Panx1-Gly) isoforms, referred to as Panx1-Gly0, -Gly1 and -Gly2 (Boassa et al., 2007; Penuela et al., 2007; Penuela et al., 2008). Interestingly, we observed that, at 5 hr, TNF treatments primarily increase only Panx1-Gly0 and Panx1-Gly1 isoforms, which were ablated by co-treatment with the protein synthesis inhibitor cycloheximide (CHX, **Figure 1B** and **Supplemental Figure 1A**), suggesting that these isoforms represent newly synthesized Panx1. To determine the specificity of TNF to Panx1 expression, we investigated the Cx43 gap junction protein in HUVECs, which did not increase following TNF stimulation and was inhibited following CHX treatments (**Figure 1B**). Following 24 hr TNF treatment, we identified significant upregulation of the Panx1-Gly2 isoform (**Supplemental Figure 1B**). Increasing the concentration of TNF treatments did not enhance Panx1 expression from 2.5 ng/mL at either 5 hr or 24 hr and did not alter expression of Cx43 (**Supplemental Figure 1A-C**). In addition, Panx1-Gly2 isoforms were not reduced by CHX (**Figure 1B**), suggesting that these represent a more stable isoform of Panx1. To investigate this, HUVECs were treated with TNF for 24 hr, washed in fresh media without TNF, and cultured for a further 8 days. Analysis by immunoblot demonstrates that while the Panx1-Gly0/1 isoforms are lost within 24 hr of removal of TNF, the Panx1-Gly2 isoforms remain significantly increased from control for 24 hr after removal of TNF and remain elevated for a further 5 days (**Figure 1C**). This demonstrates a stable, mature form of Panx1 that has a significant residence time at the plasma membrane, making it more stable than connexin proteins.

Previous studies have suggested that Panx1-Gly2 isoforms represent the mature Panx1 channels within the plasma membrane (Boassa et al., 2007). We therefore used a membrane protein biotinylation pull-down approach to isolate plasma membrane proteins and identified that Panx1-Gly2 isoforms are primarily localized within the plasma membrane 24 hr after TNF treatment (**Figure 1D**). We further demonstrate that Panx1 expression by cultured human vascular smooth muscle cells (SMC) is unaltered by TNF treatment (**Supplemental Figure 1D**). Previous studies have found TNF to reduce cell viability (Zhou et al., 2017). However, 24 hr TNF treatments ranging

from 2.5-100 ng/mL for 24 hr did not alter HUVEC viability as measured by intracellular ATP levels, caspase-3 cleavage, or by cell morphology (**Supplemental Figure 1E-G**).

TNF signaling is associated with activation of NF κ B-mediated gene regulation. Whole-transcriptome RNA sequencing (RNA-seq) experiments confirmed that TNF treatment of HUVEC significantly upregulated NF κ B genes NFKBIA, NFKBIE, NFKB1, NFKB2, NFKB1B (**Figure 1E**). To define a role for NF κ B-activated pathways in TNF-induced increases in Panx1 expression, HUVECs were pre-treated with NF κ B-inhibitors SC514 and QNZ. Both SC514 and QNZ, significantly ablated TNF-induced increases in Panx1 expression at 24 hr (**Figure 1F-G**). RNA-seq results demonstrate that TNF (2.5 ng/mL) does not alter mitogen activated protein kinase (MAPK) transcription, and MAPK inhibition failed to reduce TNF-associated Panx1 upregulation (**Supplemental Figure 1H-I**). This suggests that TNF specifically stimulates a NF κ B-mediated upregulation of Panx1 proteins, leading to plasma membrane localization of Panx1 channels in ECs.

Increased Panx1 membrane targeting is associated with the transcription and release of specific pro-inflammatory cytokines. Panx1 has been associated, but not directly implicated, in the release of molecules associated with inflammation (Chen et al., 2019; Lohman et al., 2015; Sharma et al., 2018). To investigate whether the increased Panx1 at the plasma membrane is directly associated with cytokine production and release, we first used genetic inhibition of Panx1. Panx1-siRNA reduced the basal expression of Panx1 in HUVECs and inhibited increases in Panx1 in response to TNF (**Figure 2A-B**). Cytokine arrays used to assay the media from HUVEC cells showed that TNF treatment altered the expression of a number of cytokines (**Supplemental Figure 2**). We selected key pro-inflammatory cytokines associated with atherosclerosis such as IL-1 β and CXCL10, IL8 and MCP-1 which were found to be increased in response to TNF treatment in HUVEC, unlike MIF and Basigin which were not markedly increased by TNF (**Figure 2C**). siRNA knockdown of Panx1 in HUVECs was associated with a reduction in the release of IL-1 β and CXCL10 (**Figure 2C, Supplemental Figure 2**). Notably, Panx1 siRNA treated cells displayed a significantly reduced transcription of IL-1 β and CXCL10 but showed no differences in IL8 and CCL2 (**Figure 2D-E**). Panx1 siRNA and TNF-treatments also had no effect on MIF or CD147 (**Figure 2F**). These data suggest that Panx1 critically regulates the control of specific inflammatory cytokines including IL-1 β and CXCL10. While multiple other cytokines and chemokines have been found to be increased in atherosclerosis, clinical trials targeting these pathways by treatments including low dose methotrexate has not proven to be effective in reducing the burden of disease in patients (Ridker et al., 2019). Based on this, we focused on

mechanisms controlling IL-1 β , since directly targeting IL-1 β is linked with a reduction in patient risk (Ridker et al., 2017). Critically, understanding the molecular mechanisms controlling IL-1 β expression may provide avenues for future therapeutic intervention (Brown et al., 2015; Dinarello, 2010; Libby and Hansson, 2015; Ridker, 2013, 2019).

Purinergic signaling is not a key regulator of TNF-induced IL-1 β in endothelial cells. Based on the known role for Panx1 and ATP release, which has been linked with IL-1 β regulation, we investigated ATP release from HUVECs following treatment with TNF and the corresponding effects of ATP on IL-1 β . ATP release from HUVECs was measured in media following TNF treatment at doses ranging from 2.5-100 ng/mL. All concentrations of TNF produced similar increases in ATP release from HUVECs (**Figure 3A**), which was significantly reduced following genetic inhibition of Panx1 (**Figure 3B**). While previous studies have correlated ATP treatment with regulation of IL-1 β , this has typically required ATP analogues to be applied at concentrations ranging from 100 μ M – 5 mM (Cullen et al., 2015; Kanjanamekanant et al., 2013; Mehta et al., 2001). Our data demonstrate that the HUVECs release only 10-20 nM ATP once exposed to TNF (2.5 ng/mL) for 24 hr (**Figure 3C**). At these concentrations (10 nM - 100 μ M), the ATP analogue ATPyS failed to increase IL-1 β transcription (**Figure 3D**). However, we did observe a small increase in transcription of IL-1 β at 100 μ M ATPyS, which could be ablated by pre-treating cells with the P2X inhibitor suramin (**Figure 3E**). Further data demonstrate that promoting the degradation of released ATP using apyrase or inhibition of the P2 receptors using suramin, did not significantly alter the expression of either Panx1 or IL-1 β in the presence of TNF (**Figure 3F-G**). Thus, the NF κ B-induced increase in Panx1 expression at the plasma membrane, while crucial for IL-1 β cytokine production, was not regulated by an autocrine ATP release from the EC.

TNF increases in intracellular Ca²⁺ which is regulated by the functional Panx1 channels. Increased intracellular Ca²⁺ is associated with the control of IL-1 β synthesis (Ainscough et al., 2015), and Panx1 channels have been suggested to allow the passage of Ca²⁺ from the extracellular environment into the cytosol, albeit this has never been demonstrated (Penuela et al., 2013; Vanden Abeele et al., 2006). To investigate whether Panx1 plays a role in the control of intracellular Ca²⁺ we used a high-throughput, flow cytometric approach (Vines et al., 2010), to measure intracellular Ca²⁺ in HUVECs. We found that intracellular calcium concentration ([Ca²⁺]_i) was only increased after 24 hr TNF treatment, a time that correlates with the increases in Panx1 membrane localization (**Figure 4A**). To determine whether the increase in [Ca²⁺]_i was due to extracellular Ca²⁺ (e.g., through the increased number of Panx1 channels), Ca²⁺-free Krebs ringer was used. This experiment demonstrated a significant decrease in EC [Ca²⁺]_i (**Figure 4B**). We

further demonstrated that increased intracellular Ca^{2+} is directly related to IL-1 β production, since cells loaded with EGTA-AM in the media reduced $[\text{Ca}^{2+}]_i$ which corresponded to a loss of TNF-induced IL-1 β transcription (**Figure 4C-D**). To more specifically assess whether there was a role for Panx1 in regulating EC $[\text{Ca}^{2+}]_i$, we used the Panx1-specific channel blocking peptide PxIL2P to pharmacologically inhibit Panx1 channels (Billaud et al., 2015; Good et al., 2018a). Pre-treatment of HUVECs with PxIL2P reduced $[\text{Ca}^{2+}]_i$ and IL-1 β transcription in response to 24 hr TNF treatment (**Figure 4E-F**). Similar results were found using genetic inhibition of Panx1, which reduced TNF-associated increases in $[\text{Ca}^{2+}]_i$ (**Figure 4G**) and IL-1 β (**Figure 2A**). In line with these observations, there was also a decrease in monocyte binding to EC with no change in THP1-Panx1 expression (**Supplemental Figure 3**). Lastly, levels of $[\text{Ca}^{2+}]_i$ and IL-1 β mRNA were reduced 24 hr after the removal of TNF (**Figure 2H-I**), which correlated with the same decrease in Panx1 expression at the plasma membrane seen in **Figure 1C**. This data provides additional evidence that increased Panx1 channels in EC after TNF stimulation permit the passive diffusion of extracellular Ca^{2+} into the cell, possibly to regulate IL-1 β production.

Because increased intracellular Ca^{2+} have been reported to result in phosphorylation of the NF κ B protein p65 (P-p65), increasing its transcriptional activity (Martin et al., 2001), we aimed to assess the role of Panx1 in regulating NF κ B-P-p65. HUVEC treatment with TNF (24 hr) lead to an increase in P-p65 which was significantly decreased following genetic (siRNA of Panx1) or pharmacological (PxIL2P) inhibition of Panx1 (**Figure 4J-K**). Taken together, these data suggest that Panx1 channels in the plasma membrane act as a conduit for the movement of Ca^{2+} into the cytosol, leading to activation of NF κ B signaling, which acts as a feed-forward mechanism to promote the production and release of IL-1 β .

DISCUSSION

ATP release through Panx1 channels has been shown to be a strong signal for the recruitment of inflammatory cells in response to apoptosis (Chekeni et al., 2010) and activation of the NLR3P inflammasome (Albalawi et al., 2017; Lappas, 2014; Wu et al., 2017). However, the precise Panx1-mediated mechanisms controlling inflammation have never been fully elucidated. Here we demonstrate that EC-Panx1 is a direct target of the TNF signaling pathway, promoting plasma membrane localization of the channel, which facilitates the entry of extracellular Ca^{2+} into the cytosol. Importantly, we show that increases in intracellular Ca^{2+} , resulting from enhanced Panx1 channel activity are directly associated with upregulated transcription and release of pro-inflammatory cytokines including IL-1 β .

One of the primary findings in this study is the identification of a novel mechanism for the transcriptional regulation of Panx1. We observed that EC Panx1 is acutely sensitive to TNF stimulation, with maximal increases found in the low ng/mL range. Our data suggest that this is not a ubiquitous pathway, as increases in Panx1 expression were not found in TNF-treated SMCs or monocytes. Both SMCs and monocytes express TNF receptors and form inflammatory responses to TNF-stimulation (Gane et al., 2016; Jean-Charles et al., 2018; Warner and Libby, 1989). It is possible that cell-specific variances in gene or protein regulation in these cells may be due to differential regulation of receptor activation (Gane et al., 2016) or downstream pathways, e.g. SMC ubiquitin-specific protease 20 (USP20)-deubiquitinase activity which reduces NF κ B in SMC (Jean-Charles et al., 2018). There are few studies that have investigated the transcriptional control of Panx1 and there is currently limited data on pathophysiological mechanisms controlling Panx1 expression (Boyce et al., 2018). Jiang et al. reported increases in expression of Panx1 in mouse models of inducible stroke, which are associated with increased TNF-induced inflammation and tissue injury (Bokhari et al., 2014; Jiang et al., 2012; Liu and McCullough, 2011; Tuttolomondo et al., 2009; Tuttolomondo et al., 2014). In silico analysis has highlighted a number of transcriptional start sites within the rat Panx1 sequence, with binding sites for several transcription factors including CREB and ETV4 as well as factors downstream from IL-6 that have been identified (Dufresne and Cyr, 2014). Our RNA-seq data highlighted that TNF upregulates all NF κ B genes in HUVECs. TNF-induced Panx1 transcription was lost when HUVECs were pre-treated with inhibitors shown to block NF κ B-IKKB activity and TNF production (Gong et al., 2018; Kishore et al., 2003; Tobe et al., 2003). Our data strongly suggest that NF κ B pathways regulate EC Panx1 transcription.

We also found that increases in Panx1-transcription are followed by protein translation within 5 hours that was lost when cells were treated with the protein synthesis inhibitor CHX. The newly synthesized Panx1 proteins then translocate to the plasma membrane within 24 hours. Our surface biotinylation experiments highlight that the Panx1 isoform at the plasma membrane is primarily the complex-glycoprotein isoform (Panx1-Gly2). This is in keeping with previous studies suggesting that the Panx1-Gly2 is the predominant post-translationally modified form of Panx1 in the plasma membrane that forms hexameric membrane-channels (Boassa et al., 2007; Penuela et al., 2007). Pannexins are close family members of the connexin protein family which have a protein half-life of between 1-4 hours (Laird, 2006; Laird et al., 2017). An interesting observation in our study was that, once at the plasma membrane, the Panx1-Gly2 isoform is highly stable, unlike Cx43, and may persist for several days after the removal of TNF. This represents significantly longer protein stability than previously reported in experimental models by Boassa et al., and may highlight different protein recycling pathways between cell types (Boassa et al., 2007; Boassa et al., 2008). Despite having an extended residence time at the plasma membrane, our data also reveal that Panx1 channel activity may be dependent on continued stimulation by TNF for channel opening (as described in (DeLalio et al., 2019)), since $[Ca^{2+}]_i$ were reduced to baseline within 24 hours of removal of TNF. Thus, Panx1 functions in EC are regulated by TNF through multiple mechanisms including, synthesis, translation, trafficking and channel opening via phosphorylation.

Recent clinical trials have demonstrated that inflammation plays a key role in atherosclerotic disease development and that targeting specific cytokines may provide therapeutic benefits in high risk patients (Everett et al., 2013; Ridker, 2013, 2019; Ridker et al., 2019; Ridker et al., 2017; Ridker et al., 2012). In particular, the CANTOS trial demonstrated that the canakinumab, an anti-IL-1 β therapeutic, reduces circulating levels of IL-1 β in patients and decreases major adverse coronary events. Canakinumab treatments reduce IL-1 β expression but also reduce expression of biomarkers including IL-6 and C-reactive protein (Ridker et al., 2017). However, targeting pathways associated with IL-6 expression using low-dose methotrexate, did not result in significant patient benefits (Chan and Cronstein, 2010; Cronstein et al., 1993; Ridker et al., 2019). This has led to the suggestion that atherosclerosis may be under the control of IL-1 β and that targeting pathways controlling or controlled by IL-1 β may have therapeutic benefit (Brown et al., 2015; Dinarello, 2010; Libby and Hansson, 2015; Ridker, 2013, 2019). Here we show that TNF treatment of HUVEC cells leads to release of cytokines including IL-1 β , which was significantly reduced when Panx1 expression was knocked down via siRNA. Approaches using genetic (siRNA of Panx1) or pharmacological (PxIL2P) inhibition further identified that Panx1 expression

1 and signaling can regulate IL-1 β synthesis. These data suggest that Panx1 may be involved in
2 multiple aspects of the synthesis and release of IL-1 β in EC.

3 Our data provide further evidence that the expression of other inflammatory chemokines such as
4 CXCL10 are controlled in a Panx1 specific manner. CXCL10 has been proposed to be an
5 important inflammatory marker in atherosclerosis (Szentos et al., 2018; Zernecke et al., 2008),
6 leading to the formation of vulnerable plaques in humans and mice (Heller et al., 2006; Segers et
7 al., 2011). Strategies to lower CXCL10 expression can lead to reduced plaque formation and
8 increased plaque stability (Segers et al., 2011). As previously described, it is possible that these
9 increases correlate with IL-1 β signaling pathways (Brown et al., 2015; Dinarello, 2010; Libby and
10 Hansson, 2015; Ridker, 2013, 2019). However, the mechanisms through which Panx1 regulates
11 these cytokines and chemokines remain to be fully elucidated.

12 The primary focus for signaling via Panx1 channels has been the release of ATP following channel
13 opening (Chekeni et al., 2010; Lohman et al., 2015; Romanov et al., 2012), although other
14 molecules are assumed to pass through these high conductance channels (Chiu et al., 2018;
15 Vanden Abeele et al., 2006). Panx1 mediated ATP release has been associated with direct
16 recruitment of inflammatory cells (Lohman et al., 2015), or through P2X receptor mediated
17 pathways (Pelegrin, 2008). Receptor signaling via P2X receptors has leads to increases in the
18 processing of pro-IL-1 β to its mature form and with IL-1 β release (Ainscough et al., 2015; Brough
19 et al., 2003). Panx1-associated ATP release increases in Caspase 1 and Pro- IL-1 β processing
20 in human gestational tissues promoting (Lappas, 2014). In astrocytes, Panx1 mediated ATP
21 release and signaling through the P2X7 channel, has been found promote activation of the NLRP3
22 inflammasome and the release of IL-1 β (Albalawi et al., 2017). Our results show that TNF
23 treatments (2.5-100 ng/mL) of HUVECs resulted in the release of approximately 10-20 nM ATP,
24 which is similar to previous reports (Tozzi et al., 2019). Nonetheless, we found that adding
25 exogenous ATP (data not shown) or the stable ATP isoform (ATP- γ S) at these concentrations
26 was not sufficient to stimulate IL-1 β transcription. In previous studies, non-physiological levels of
27 ATP (e.g., as high as 5 mM) induce IL-1 β transcription (Cullen et al., 2015; Kanjanamekanant et
28 al., 2013; Mehta et al., 2001). In keeping with these observations, we found that treatment of
29 HUVECs with 100 μ M ATP- γ S did induce an increase IL-1 β transcription, that was inhibited by
30 the P2X inhibitor suramin. However, it should be noted that the ATP-induced IL-1 β responses
31 were significantly lower than those following TNF stimulation in our study. Furthermore, TNF-
32 induced IL-1 β and Panx1 expression in HUVECs was not altered by co-treatment with apyrase
33 (to degrade ATP) or in the presence of suramin (to block P2X receptors). Taken together, these

data suggest that ATP is not the primary mechanism for alterations in IL-1 β synthesis in HUVECs following TNF treatment.

Panx1 channels are permeable to ions and molecules up to 1 KDa, and Vanden Abeele et al. previously demonstrated that Panx1 channels in the endoplasmic reticulum facilitates the movement of Ca²⁺ (Vanden Abeele et al., 2006). Here, we found that [Ca²⁺]_i was increased in HUVEC cells in response to TNF. Interestingly, this did not occur at earlier timepoints (5 hr) suggesting that kinase activation of TNF pathways is not involved. Rather, increases in intracellular Ca²⁺ were only found after long-term stimulation of up to 24 hr, a timepoint at which we demonstrate Panx1 channels are functional at the plasma membrane. To assess the source of increased intracellular Ca²⁺ we repeated the TNF stimulation experiment in Ca²⁺ free Krebs solution, which blocked the response, suggesting that increases in intracellular Ca²⁺ originated from outside the cell. While it is possible that other mechanisms serve to facilitate the entry of Ca²⁺ under these conditions, we provide several lines of evidence that suggest that Panx1 channels are directly permeable to Ca²⁺, these include no Ca²⁺ response to TNF when Panx1 is silenced by siRNA or the channel is inhibited using the Panx1 specific inhibitor peptide PxIL2P. Our data show that increases in intracellular Ca²⁺ are associated with IL-1 β -synthesis, that can be ablated following reductions in intracellular Ca²⁺ using EGTA-AM and by blocking the Panx1 channel. Our data therefore suggest that plasma membrane Panx1 channels are permeable to, and facilitate increases in [Ca²⁺]_i.

The NF κ B-p65 protein, is a downstream target of TNF signaling, and blocking its activation significantly alters TNF associated gene regulation, including IL-1 β (Perrot-Appianat et al., 2011). Here, we have demonstrated that NF κ B activation plays a key role in early upregulation of Panx1 in EC, which promotes its membrane trafficking and channel opening. While Panx1 is a direct target of NF κ B activation, we further demonstrate that Panx1 signaling can enhance NF κ B activation. This is in keeping with studies by Wu et al that pointed to a role of Panx1 in the control of NF κ B activation (Wu et al., 2017). Our data highlight that TNF induces an increase in P-p65 activation, that is significantly reduced when Panx1 expression is knocked down by siRNA and when the channel is blocked in the presence of the PxIL2P peptide. In vitro, our results do not lead to a complete reduction in IL-1 β expression, which may suggest that the role of Panx1-Ca²⁺ signaling is to amplify the NF κ B-mediated responses, through Ca²⁺-mediated phosphorylation of p65, as previously described (Martin et al., 2001). Thus, we propose that Panx1 facilitates a feed-forward signaling through Ca²⁺ leading to the transcriptional control of IL-1 β .

- 1 Taken together our study highlights a novel reciprocal relationship between TNF and NFκβ
- 2 signaling, which is regulated by Panx1 channel mediated control of intracellular Ca²⁺, leading to
- 3 alterations in IL-1β synthesis and release by ECs.

1 **STAR** ★ **METHODS**

2 Detailed methods are provided in the online version of this paper and include the following:

3• **KEY RESOURCE TABLE**

4• **CONTACT FOR REAGENT AND RESOURCE SHARING**

5• **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

6○ Primary cells and cell lines

7• **METHOD DETAILS**

8○ Cell culture

9○ Cell transfection

10○ Cell treatment

11○ RNA extraction RT-qPCR and RNA seq

12○ Immunoblotting and membrane protein biotinylation

13○ Cytokine array

14○ Luciferase assay for ATP measurements

15○ Flow cytometric analysis of intracellular calcium and monocyte adhesion

16• **QUANTIFICATION AND STATISTICAL ANALYSIS**

REFERENCES

- Adhikary, G., Sun, Y., and Pearlman, E. (2008). C-Jun NH2 terminal kinase (JNK) is an essential mediator of Toll-like receptor 2-induced corneal inflammation. *J Leukoc Biol* 83, 991-997.
- Ainscough, J.S., Gerberick, G.F., Kimber, I., and Dearman, R.J. (2015). Interleukin-1 β Processing Is Dependent on a Calcium-mediated Interaction with Calmodulin. *J Biol Chem* 290, 31151-31161.
- Albalawi, F., Lu, W., Beckel, J.M., Lim, J.C., McCaughey, S.A., and Mitchell, C.H. (2017). The P2X7 Receptor Primes IL-1 β and the NLRP3 Inflammasome in Astrocytes Exposed to Mechanical Strain. *Front Cell Neurosci* 11, 227.
- Alexander, M.R., Moehle, C.W., Johnson, J.L., Yang, Z., Lee, J.K., Jackson, C.L., and Owens, G.K. (2012). Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. *J Clin Invest* 122, 70-79.
- Barath, P., Fishbein, M.C., Cao, J., Berenson, J., Helfant, R.H., and Forrester, J.S. (1990). Detection and localization of tumor necrosis factor in human atheroma. *Am J Cardiol* 65, 297-302.
- Billaud, M., Chiu, Y.H., Lohman, A.W., Parpaite, T., Butcher, J.T., Mutchler, S.M., DeLalio, L.J., Artamonov, M.V., Sandilos, J.K., Best, A.K., *et al.* (2015). A molecular signature in the pannexin1 intracellular loop confers channel activation by the alpha1 adrenoreceptor in smooth muscle cells. *Sci Signal* 8, ra17.
- Billaud, M., Lohman, A.W., Straub, A.C., Looft-Wilson, R., Johnstone, S.R., Araj, C.A., Best, A.K., Chekeni, F.B., Ravichandran, K.S., Penuela, S., *et al.* (2011). Pannexin1 Regulates alpha 1-Adrenergic Receptor-Mediated Vasoconstriction. *Circulation Research* 109, 80-U284.
- Boassa, D., Ambrosi, C., Qiu, F., Dahl, G., Gaietta, G., and Sosinsky, G. (2007). Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane. *J Biol Chem* 282, 31733-31743.
- Boassa, D., Qiu, F., Dahl, G., and Sosinsky, G. (2008). Trafficking dynamics of glycosylated pannexin 1 proteins. *Cell Commun Adhes* 15, 119-132.
- Bokhari, F.A., Shakoori, T.A., Butt, A., and Ghafoor, F. (2014). TNF-alpha: a risk factor for ischemic stroke. *J Ayub Med Coll Abbottabad* 26, 111-114.
- Boyce, A.K.J., Epp, A.L., Nagarajan, A., and Swayne, L.A. (2018). Transcriptional and post-translational regulation of pannexins. *Biochim Biophys Acta Biomembr* 1860, 72-82.

- 1 Bradley, J.R. (2008). TNF-mediated inflammatory disease. *J Pathol* 214, 149-160.
- 2 Brough, D., Le Feuvre, R.A., Wheeler, R.D., Solovyova, N., Hilfiker, S., Rothwell, N.J., and
3 Verkhatsky, A. (2003). Ca²⁺ stores and Ca²⁺ entry differentially contribute to the release of IL-
4 1 beta and IL-1 alpha from murine macrophages. *J Immunol* 170, 3029-3036.
- 5 Brown, W.V., Remaley, A.T., and Ridker, P.M. (2015). JCL Roundtable: is inflammation a future
6 target in preventing arteriosclerotic cardiovascular disease. *J Clin Lipidol* 9, 119-128.
- 7 Chan, E.S., and Cronstein, B.N. (2010). Methotrexate--how does it really work? *Nat Rev*
8 *Rheumatol* 6, 175-178.
- 9 Chekeni, F.B., Elliott, M.R., Sandilos, J.K., Walk, S.F., Kinchen, J.M., Lazarowski, E.R.,
10 Armstrong, A.J., Penuela, S., Laird, D.W., Salvesen, G.S., *et al.* (2010). Pannexin 1 channels
11 mediate 'find-me' signal release and membrane permeability during apoptosis. *Nature* 467, 863-
12 867.
- 13 Chen, K.W., Demarco, B., and Broz, P. (2019). Pannexin-1 promotes NLRP3 activation during
14 apoptosis but is dispensable for canonical or Non-canonical inflammasome activation. *Eur J*
15 *Immunol*.
- 16 Chiu, Y.H., Schappe, M.S., Desai, B.N., and Bayliss, D.A. (2018). Revisiting multimodal activation
17 and channel properties of Pannexin 1. *J Gen Physiol* 150, 19-39.
- 18 Cronstein, B.N., Naime, D., and Ostad, E. (1993). The antiinflammatory mechanism of
19 methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation
20 in an in vivo model of inflammation. *J Clin Invest* 92, 2675-2682.
- 21 Cullen, S.P., Kearney, C.J., Clancy, D.M., and Martin, S.J. (2015). Diverse Activators of the
22 NLRP3 Inflammasome Promote IL-1 β Secretion by Triggering Necrosis. *Cell Rep* 11, 1535-1548.
- 23 DeLalio, L.J., Billaud, M., Ruddiman, C.A., Johnstone, S.R., Butcher, J.T., Wolpe, A.G., Jin, X.,
24 Keller, T.C.S., Keller, A.S., Rivière, T., *et al.* (2019). Constitutive SRC-mediated phosphorylation
25 of pannexin 1 at tyrosine 198 occurs at the plasma membrane. *J Biol Chem*.
- 26 Di Minno, M.N., Iervolino, S., Peluso, R., Scarpa, R., Di Minno, G., and group, C.s. (2011). Carotid
27 intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor- α blockers
28 and traditional disease-modifying antirheumatic drugs. *Arterioscler Thromb Vasc Biol* 31, 705-
29 712.
- 30 Dinarello, C.A. (2010). Anti-inflammatory Agents: Present and Future. *Cell* 140, 935-950.

- 1 Dufresne, J., and Cyr, D.G. (2014). Regulation of the pannexin-1 promoter in the rat epididymis.
2 Biol Reprod 91, 143.
- 3 Everett, B.M., Pradhan, A.D., Solomon, D.H., Paynter, N., Macfadyen, J., Zaharris, E., Gupta, M.,
4 Clearfield, M., Libby, P., Hasan, A.A., *et al.* (2013). Rationale and design of the Cardiovascular
5 Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am
6 Heart J 166, 199-207 e115.
- 7 Gabay, C., McInnes, I.B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., and Sattar, N.
8 (2016). Comparison of lipid and lipid-associated cardiovascular risk marker changes after
9 treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis
10 75, 1806-1812.
- 11 Gane, J.M., Stockley, R.A., and Sapey, E. (2016). TNF-. J Immunol Res 2016, 1079851.
- 12 Gong, K., Guo, G., Gerber, D.E., Gao, B., Peyton, M., Huang, C., Minna, J.D., Hatanpaa, K.J.,
13 Kernstine, K., Cai, L., *et al.* (2018). TNF-driven adaptive response mediates resistance to EGFR
14 inhibition in lung cancer. J Clin Invest 128, 2500-2518.
- 15 Good, M.E., Chiu, Y.H., Poon, I.K.H., Medina, C.B., Butcher, J.T., Mendu, S.K., DeLalio, L.J.,
16 Lohman, A.W., Leitinger, N., Barrett, E., *et al.* (2018a). Pannexin 1 Channels as an Unexpected
17 New Target of the Anti-Hypertensive Drug Spironolactone. Circ Res 122, 606-615.
- 18 Good, M.E., Eucker, S.A., Li, J., Bacon, H.M., Lang, S.M., Butcher, J.T., Johnson, T.J., Gaykema,
19 R.P., Patel, M.K., Zuo, Z., *et al.* (2018b). Endothelial cell Pannexin1 modulates severity of
20 ischemic stroke by regulating cerebral inflammation and myogenic tone. JCI Insight 3.
- 21 Heller, E.A., Liu, E., Tager, A.M., Yuan, Q., Lin, A.Y., Ahluwalia, N., Jones, K., Koehn, S.L., Lok,
22 V.M., Aikawa, E., *et al.* (2006). Chemokine CXCL10 promotes atherogenesis by modulating the
23 local balance of effector and regulatory T cells. Circulation 113, 2301-2312.
- 24 Imaizumi, T., Itaya, H., Fujita, K., Kudoh, D., Kudoh, S., Mori, K., Fujimoto, K., Matsumiya, T.,
25 Yoshida, H., and Satoh, K. (2000). Expression of tumor necrosis factor-alpha in cultured human
26 endothelial cells stimulated with lipopolysaccharide or interleukin-1alpha. Arterioscler Thromb
27 Vasc Biol 20, 410-415.
- 28 Jantaratnotai, N., Choi, H.B., and McLarnon, J.G. (2009). ATP stimulates chemokine production
29 via a store-operated calcium entry pathway in C6 glioma cells. BMC cancer 9, 442.
- 30 Jean-Charles, P.Y., Wu, J.H., Zhang, L., Kaur, S., Nepliouev, I., Stiber, J.A., Brian, L., Qi, R.,
31 Wertman, V., Shenoy, S.K., *et al.* (2018). USP20 (Ubiquitin-Specific Protease 20) Inhibits TNF

1 (Tumor Necrosis Factor)-Triggered Smooth Muscle Cell Inflammation and Attenuates
2 Atherosclerosis. *Arterioscler Thromb Vasc Biol* 38, 2295-2305.

3 Jiang, T., Xu, R.X., Zhang, A.W., Di, W., Xiao, Z.J., Miao, J.Y., Luo, N., and Fang, Y.N. (2012).
4 Effects of transcranial direct current stimulation on hemichannel pannexin-1 and neural plasticity
5 in rat model of cerebral infarction. *Neuroscience* 226, 421-426.

6 Kanjanamekanant, K., Luckprom, P., and Pavasant, P. (2013). Mechanical stress-induced
7 interleukin-1 β expression through adenosine triphosphate/P2X7 receptor activation in human
8 periodontal ligament cells. *J Periodontal Res* 48, 169-176.

9 Kishore, N., Sommers, C., Mathialagan, S., Guzova, J., Yao, M., Hauser, S., Huynh, K., Bonar,
10 S., Mielke, C., Albee, L., *et al.* (2003). A selective IKK-2 inhibitor blocks NF-kappa B-dependent
11 gene expression in interleukin-1 beta-stimulated synovial fibroblasts. *J Biol Chem* 278, 32861-
12 32871.

13 Laird, D.W. (2006). Life cycle of connexins in health and disease. *Biochem J* 394, 527-543.

14 Laird, D.W., Naus, C.C., and Lampe, P.D. (2017). SnapShot: Connexins and Disease. *Cell* 170,
15 1260-1260.e1261.

16 Lappas, M. (2014). Caspase-1 activation is increased with human labour in foetal membranes
17 and myometrium and mediates infection-induced interleukin-1 β secretion. *Am J Reprod Immunol*
18 71, 189-201.

19 Libby, P., and Hansson, G.K. (2015). Inflammation and immunity in diseases of the arterial tree:
20 players and layers. *Circ Res* 116, 307-311.

21 Libby, P., Lichtman, A.H., and Hansson, G.K. (2013). Immune effector mechanisms implicated in
22 atherosclerosis: from mice to humans. *Immunity* 38, 1092-1104.

23 Liu, F., and McCullough, L.D. (2011). Middle cerebral artery occlusion model in rodents: methods
24 and potential pitfalls. *J Biomed Biotechnol* 2011, 464701.

25 Lohman, A.W., Leskov, I.L., Butcher, J.T., Johnstone, S.R., Stokes, T.A., Begandt, D., DeLalio,
26 L.J., Best, A.K., Penuela, S., Leitinger, N., *et al.* (2015). Pannexin 1 channels regulate leukocyte
27 emigration through the venous endothelium during acute inflammation. *Nat Commun* 6, 7965.

28 Maitre, B., Magnenat, S., Heim, V., Ravanat, C., Evans, R.J., de la Salle, H., Gachet, C., and
29 Hechler, B. (2015). The P2X1 Receptor Is Required for Neutrophil Extravasation during
30 Lipopolysaccharide-Induced Lethal Endotoxemia in Mice. *Journal of immunology* 194, 739-749.

- 1 Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W.P.,
2 Weinrauch, Y., Monack, D.M., and Dixit, V.M. (2006). Cryopyrin activates the inflammasome in
3 response to toxins and ATP. *Nature* 440, 228-232.
- 4 Martin, A.G., San-Antonio, B., and Fresno, M. (2001). Regulation of nuclear factor kappa B
5 transactivation. Implication of phosphatidylinositol 3-kinase and protein kinase C zeta in c-Rel
6 activation by tumor necrosis factor alpha. *J Biol Chem* 276, 15840-15849.
- 7 Mehta, V.B., Hart, J., and Wewers, M.D. (2001). ATP-stimulated release of interleukin (IL)-1beta
8 and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. *J*
9 *Biol Chem* 276, 3820-3826.
- 10 Orellana, J.A., Froger, N., Ezan, P., Jiang, J.X., Bennett, M.V., Naus, C.C., Giaume, C., and Sáez,
11 J.C. (2011). ATP and glutamate released via astroglial connexin 43 hemichannels mediate
12 neuronal death through activation of pannexin 1 hemichannels. *J Neurochem* 118, 826-840.
- 13 Pelegrin, P. (2008). Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7)
14 receptor and Pannexin-1. *Drug News Perspect* 21, 424-433.
- 15 Penuela, S., Bhalla, R., Gong, X.Q., Cowan, K.N., Celetti, S.J., Cowan, B.J., Bai, D., Shao, Q.,
16 and Laird, D.W. (2007). Pannexin 1 and pannexin 3 are glycoproteins that exhibit many distinct
17 characteristics from the connexin family of gap junction proteins. *J Cell Sci* 120, 3772-3783.
- 18 Penuela, S., Celetti, S.J., Bhalla, R., Shao, Q., and Laird, D.W. (2008). Diverse subcellular
19 distribution profiles of pannexin 1 and pannexin 3. *Cell Commun Adhes* 15, 133-142.
- 20 Penuela, S., Gehi, R., and Laird, D.W. (2013). The biochemistry and function of pannexin
21 channels. *Biochim Biophys Acta* 1828, 15-22.
- 22 Perrot-Applanat, M., Vacher, S., Toullec, A., Pelaez, I., Velasco, G., Cormier, F., Saad, H.I.S.,
23 Lidereau, R., Baud, V., and Bièche, I. (2011). Similar NF-κB gene signatures in TNF-α treated
24 human endothelial cells and breast tumor biopsies. *PLoS One* 6, e21589.
- 25 Qu, Y., Misaghi, S., Newton, K., Gilmour, L.L., Louie, S., Cupp, J.E., Dubyak, G.R., Hackos, D.,
26 and Dixit, V.M. (2011). Pannexin-1 is required for ATP release during apoptosis but not for
27 inflammasome activation. *J Immunol* 186, 6553-6561.
- 28 Ridker, P.M. (2013). Closing the loop on inflammation and atherothrombosis: why perform the
29 CIRT and CANTOS trials? *Trans Am Clin Climatol Assoc* 124, 174-190.
- 30 Ridker, P.M. (2019). Anti-inflammatory therapy for atherosclerosis: interpreting divergent results
31 from the CANTOS and CIRT clinical trials. *J Intern Med* 285, 503-509.

- 1 Ridker, P.M., Everett, B.M., Pradhan, A., MacFadyen, J.G., Solomon, D.H., Zaharris, E., Mam,
2 V., Hasan, A., Rosenberg, Y., Iturriaga, E., *et al.* (2019). Low-Dose Methotrexate for the
3 Prevention of Atherosclerotic Events. *N Engl J Med* 380, 752-762.
- 4 Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., Fonseca,
5 F., Nicolau, J., Koenig, W., Anker, S.D., *et al.* (2017). Antiinflammatory Therapy with
6 Canakinumab for Atherosclerotic Disease. *N Engl J Med* 377, 1119-1131.
- 7 Ridker, P.M., Howard, C.P., Walter, V., Everett, B., Libby, P., Hensen, J., Thuren, T., and Group,
8 C.P.I. (2012). Effects of interleukin-1 β inhibition with canakinumab on hemoglobin A1c, lipids, C-
9 reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
10 *Circulation* 126, 2739-2748.
- 11 Ridker, P.M., Libby, P., MacFadyen, J.G., Thuren, T., Ballantyne, C., Fonseca, F., Koenig, W.,
12 Shimokawa, H., Everett, B.M., and Glynn, R.J. (2018). Modulation of the interleukin-6 signalling
13 pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the
14 Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J* 39, 3499-
15 3507.
- 16 Ridker, P.M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., and Braunwald, E. (2000). Elevation of
17 tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial
18 infarction. *Circulation* 101, 2149-2153.
- 19 Romanov, R.A., Bystrova, M.F., Rogachevskaya, O.A., Sadovnikov, V.B., Shestopalov, V.I., and
20 Kolesnikov, S.S. (2012). The ATP permeability of pannexin 1 channels in a heterologous system
21 and in mammalian taste cells is dispensable. *J Cell Sci* 125, 5514-5523.
- 22 Segers, D., Lipton, J.A., Leenen, P.J., Cheng, C., Tempel, D., Pasterkamp, G., Moll, F.L., de
23 Crom, R., and Krams, R. (2011). Atherosclerotic Plaque Stability Is Affected by the Chemokine
24 CXCL10 in Both Mice and Humans. *Int J Inflam* 2011, 936109.
- 25 Sharma, A.K., Charles, E.J., Zhao, Y., Narahari, A.K., Baderdinni, P.K., Good, M.E., Lorenz, U.M.,
26 Kron, I.L., Bayliss, D.A., Ravichandran, K.S., *et al.* (2018). Pannexin 1 channels on endothelial
27 cells mediate vascular inflammation during lung ischemia-reperfusion injury. *Am J Physiol Lung*
28 *Cell Mol Physiol*.
- 29 Solomon, D.H., Glynn, R.J., MacFadyen, J.G., Libby, P., Thuren, T., Everett, B.M., and Ridker,
30 P.M. (2018). Relationship of Interleukin-1 β Blockade With Incident Gout and Serum Uric Acid
31 Levels: Exploratory Analysis of a Randomized Controlled Trial. *Ann Intern Med* 169, 535-542.

1 Stoffels, M., Zaal, R., Kok, N., van der Meer, J.W., Dinarello, C.A., and Simon, A. (2015). ATP-
2 Induced IL-1 β Specific Secretion: True Under Stringent Conditions. *Front Immunol* 6, 54.

3 Szentes, V., Gazdag, M., Szokodi, I., and Dézsi, C.A. (2018). The Role of CXCR3 and Associated
4 Chemokines in the Development of Atherosclerosis and During Myocardial Infarction. *Front*
5 *Immunol* 9, 1932.

6 Thompson, R.J., Jackson, M.F., Olah, M.E., Rungta, R.L., Hines, D.J., Beazely, M.A., MacDonald,
7 J.F., and MacVicar, B.A. (2008). Activation of pannexin-1 hemichannels augments aberrant
8 bursting in the hippocampus. *Science* 322, 1555-1559.

9 Tobe, M., Isobe, Y., Tomizawa, H., Nagasaki, T., Takahashi, H., Fukazawa, T., and Hayashi, H.
10 (2003). Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B
11 activation. *Bioorg Med Chem* 11, 383-391.

12 Tozzi, M., Hansen, J.B., and Novak, I. (2019). Pannexin-1 mediated ATP release in adipocytes is
13 sensitive to glucose and insulin and modulates lipolysis and macrophage migration. *Acta Physiol*
14 *(Oxf)*, e13360.

15 Tuttolomondo, A., Di Sciacca, R., Di Raimondo, D., Renda, C., Pinto, A., and Licata, G. (2009).
16 Inflammation as a therapeutic target in acute ischemic stroke treatment. *Curr Top Med Chem* 9,
17 1240-1260.

18 Tuttolomondo, A., Pecoraro, R., and Pinto, A. (2014). Studies of selective TNF inhibitors in the
19 treatment of brain injury from stroke and trauma: a review of the evidence to date. *Drug Des Devel*
20 *Ther* 8, 2221-2238.

21 Vanden Abeele, F., Bidaux, G., Gordienko, D., Beck, B., Panchin, Y.V., Baranova, A.V., Ivanov,
22 D.V., Skryma, R., and Prevarskaya, N. (2006). Functional implications of calcium permeability of
23 the channel formed by pannexin 1. *J Cell Biol* 174, 535-546.

24 Viemann, D., Goebeler, M., Schmid, S., Nordhues, U., Klimmek, K., Sorg, C., and Roth, J. (2006).
25 TNF induces distinct gene expression programs in microvascular and macrovascular human
26 endothelial cells. *J Leukoc Biol* 80, 174-185.

27 Vigont, V.A., Zimina, O.A., Glushankova, L.N., Bezprozvanny, I.B., Mozhayeva, G.N., and
28 Kaznacheyeva, E. (2012). Store-operated calcium entry into SK-N-SH human neuroblastoma
29 cells modeling huntington's disease. *Biochemistry (Moscow) Supplemental Series A: Membrane*
30 *and Cell Biology* 6, 206-214.

- 1 Vines, A., McBean, G.J., and Blanco-Fernández, A. (2010). A flow-cytometric method for
2 continuous measurement of intracellular Ca(2+) concentration. *Cytometry A* 77, 1091-1097.
- 3 Virone, A., Bastard, J.P., Fellahi, S., Capeau, J., Rouanet, S., Sibilia, J., Ravaud, P., Berenbaum,
4 F., Gottenberg, J.E., and Sellam, J. (2019). Comparative effect of tumour necrosis factor inhibitors
5 versus other biological agents on cardiovascular risk-associated biomarkers in patients with
6 rheumatoid arthritis. *RMD Open* 5, e000897.
- 7 Warner, S.J., and Libby, P. (1989). Human vascular smooth muscle cells. Target for and source
8 of tumor necrosis factor. *J Immunol* 142, 100-109.
- 9 Wilson, H.L., Varcoe, R.W., Stokes, L., Holland, K.L., Francis, S.E., Dower, S.K., Surprenant, A.,
10 and Crossman, D.C. (2007). P2X receptor characterization and IL-1/IL-1Ra release from human
11 endothelial cells. *British journal of pharmacology* 151, 115-127.
- 12 Wu, L.Y., Ye, Z.N., Zhou, C.H., Wang, C.X., Xie, G.B., Zhang, X.S., Gao, Y.Y., Zhang, Z.H., Zhou,
13 M.L., Zhuang, Z., *et al.* (2017). Roles of Pannexin-1 Channels in Inflammatory Response through
14 the TLRs/NF-Kappa B Signaling Pathway Following Experimental Subarachnoid Hemorrhage in
15 Rats. *Front Mol Neurosci* 10, 175.
- 16 Yaron, J.R., Gangaraju, S., Rao, M.Y., Kong, X., Zhang, L., Su, F., Tian, Y., Glenn, H.L., and
17 Meldrum, D.R. (2015). K(+) regulates Ca(2+) to drive inflammasome signaling: dynamic
18 visualization of ion flux in live cells. *Cell Death Dis* 6, e1954.
- 19 Zernecke, A., Shagdarsuren, E., and Weber, C. (2008). Chemokines in atherosclerosis: an
20 update. *Arterioscler Thromb Vasc Biol* 28, 1897-1908.
- 21 Zhou, P., Lu, S., Luo, Y., Wang, S., Yang, K., Zhai, Y., Sun, G., and Sun, X. (2017). Attenuation
22 of TNF-α-Induced Inflammatory Injury in Endothelial Cells by Ginsenoside Rb1 via Inhibiting NF-
23 κB, JNK and p38 Signaling Pathways. *Front Pharmacol* 8, 464.

1 STAR ★ METHODS

2 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Pannexin-1 (D9M1C) Rabbit mAb antibody	Cell Signaling Technology	Cat# 91137, RRID:AB_2800167
Rabbit Anti-Human / Rat Connexin-43 Antibody, Unconjugated	Sigma-Aldrich	Cat# C6219, RRID:AB_476857
Mouse Anti-beta-Tubulin Monoclonal Antibody, Unconjugated, Clone Tub2.1	Sigma-Aldrich	Cat# T5201, RRID:AB_609915
NF-κB p65 (L8F6) Mouse mAb	Cell Signaling Technology	Cat# 6956, RRID:AB_10828935
Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb	Cell Signaling Technology	Cat# 3033, RRID:AB_331284
Caspase 3, rabbit polyclonal	Santa Cruz Biotechnology	Cat# SC-7148
CellTitre Glo 2.0	Promega	Cat# G9242
GAPDH mouse (mAB)	ThermoFisher Scientific	Cat# A21994
Goat Anti-Rabbit IgG, IRDye® 800CW Conjugated antibody	LI-COR Biosciences	Cat# 926-32211, RRID:AB_621843
Goat Anti-Mouse IgG, IRDye® 800CW Conjugated antibody	Goat Anti-Mouse IgG, IRDye® 800CW Conjugated antibody	Cat# 926-32210, RRID:AB_621842
IRDy(R) 680RD Goat anti-Rabbit IgG (H + L) antibody	LI-COR Biosciences	Cat# 925-68071, RRID:AB_2721181

IRDye 680RD Goat anti-Mouse IgG (H + L) antibody	LI-COR Biosciences	Cat# 926-68170, RRID:AB_10956589
IRDye®800CW Streptavidin	LI-COR Biosciences	Cat# 926-32230
Chemicals, Peptides, and Recombinant proteins		
VWR Life Science Seradigm Premium Grade Fetal Bovine Serum	VWR Life Science	Cat# 97068-085
Trypsin-EDTA (0.5%), no phenol red	ThermoFisher Scientific	Cat# 15400054
Gibco™ Medium 200	ThermoFisher Scientific	Cat# M200500
Gibco™ M231 media	ThermoFisher Scientific	Cat# M-231-500
Gibco™ RPMI media	ThermoFisher Scientific	Cat# 22400-089
Gibco™ Low Serum Growth Supplement (LSGS)	ThermoFisher Scientific	Cat# S00310
Gibco™ Low Serum Growth Supplement (LSGS)	ThermoFisher Scientific	Cat# S003K
Pierce™ Dimethylsulfoxide (DMSO), LC-MS Grade	ThermoFisher Scientific	Cat# 85190
DPBS (10X), no calcium, no magnesium	ThermoFisher Scientific	Cat# 14200075
Recombinant Human TNF-alpha Protein	R&D systems	Cat# 210-TA
Adenosine 5'-(γ-thio)-triphosphate (lithium salt)	Cayman chemical company	Cat# 14957
Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem	Sigma-Aldrich	Cat# 574625

Apyrase	Sigma-Aldrich	Cat# A6237
Carbenoxolone	MP Biomedicals	Cat# 154930
Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid	Sigma-Aldrich	Cat# E4378
SC514	Selleck	Cat# S4907
QNZ (EVP4593)	Selleck	Cat# S4902
SB203580	Selleck	Cat# S1076
Cycloheximide (CHX)	Sigma-Aldrich	Cat# 66-81-9
Panx1 IL2 peptide: [NH ₂]KYPIVEQYLKYGRKKQRRR[COOH]	ThermoFisher Scientific	Cat# A1849-1
Scramble IL2 [NH ₂]YPIKQLVKYEYGRKKQRRR[COOH]	ThermoFisher Scientific	Cat# A1849-2
Protease Inhibitor Cocktail	Sigma-Aldrich	Cat# P8340
phosphatase Inhibitor Cocktail 2	Sigma-Aldrich	Cat# P5726
phosphatase Inhibitor Cocktail 3	Sigma-Aldrich	Cat# P0044
RNeasy kit	Qiagen	Cat# 74104
Odyssey Blocking Buffer (PBS)	LI-COR Biosciences	Cat# 927-40000
Streptavidin–Agarose from Streptomyces avidinii	Sigma-Aldrich	Cat# S1638
Invitrogen™ Nuclease-Free Water (not DEPC-Treated)	ThermoFisher Scientific	Cat# AM9937
Silencer® Select Panx1	ThermoFisher Scientific	Cat# 4392420, ID:S24427
Silencer® Select Negative Control #1 siRNA	ThermoFisher Scientific	Cat# 4390843
Smooth muscle growth supplement (SMGS)	ThermoFisher Scientific	S00725

Lipofectamine™ 3000 Transfection Reagent	ThermoFisher Scientific	Cat# L3000075
EZ-Link™ Sulfo-NHS-LC-Biotin	ThermoFisher Scientific	Cat# 21335
Invitrogen™ Fluo-4, AM, cell permeant	ThermoFisher Scientific	Cat# F14201
GAPDH Hs00266705_g1	ThermoFisher Scientific	Cat# 4331182
CXCL10 Hs00171042_m1	ThermoFisher Scientific	Cat# 4331182
MIF Hs00236988_g1	ThermoFisher Scientific	Cat# 4331182
Panx1 Hs00209790_m1	ThermoFisher Scientific	Cat# 4331182
CD147 (BSG) Hs00174305_m1	ThermoFisher Scientific	Cat# 4331182
IL-1B Hs00174097_m1	ThermoFisher Scientific	Cat# 4331182
IL8 (CXLC8) Hs01283933_cn	ThermoFisher Scientific	Cat# 4400291
CCL2 Hs01104951_cn	ThermoFisher Scientific	Cat # 4400291
TaqMan™ Gene Expression Master Mix	ThermoFisher Scientific	Cat# 4369016
Critical Commercial Assays		
Invitrogen™ SuperScript™ III First-Strand Synthesis System	ThermoFisher Scientific	Cat# 18080051

Aurum™ Total RNA Fatty and Fibrous Tissue Kit	Bio-Rad	Cat# 7326830
Pierce™ BCA Protein Assay Kit	ThermoFisher Scientific	Cat# 23225
REVERT™ Total Protein Stain for immunoblot Normalization	LI-COR Biosciences	Cat# 926-11010
ATP Bioluminescence Assay Kit CLS II	Roche	Cat# 11699695001
Proteome Profiler Human XL Cytokine Array Kit	R&D systems	Cat# ARY022B
Experimental Models: Cell lines		
HUVEC	Cell Applications	200K-05n
HUVEC	Thermo Fisher	C0035C
HUVEC	Thermo Fisher	C0155C
HCASMC	Thermo Fisher	C0175C
THP1 monocytes	ATCC	TIB-202

- 1
- 2 **CONTACT FOR REAGENT AND RESOURCE SHARING**
- 3 Further information and requests for resources and reagents should be directed to and will be
- 4 fulfilled by the Lead Contact, Scott R. Johnstone, PhD.(srj6n@virginia.edu)

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Primary cells and cell lines

Human umbilical vein endothelial cells (HUVEC) and human coronary artery smooth muscle cells (SMC) were purchased from ThermoFisher and cell applications. Human THP1 cells were a kind gift Professor Zhen Yan, UVA.

METHOD DETAILS

Cell Culture

HUVECs were grown in M200 media supplemented with the low serum growth kit and 20% FCS (20%-M200). For experiments involving TNF treatments, cells were incubated in M200 with low serum growth kit and 0.1% serum (0.1%-M200) for 24 hr. Human coronary artery smooth muscle cells (SMC, ThermoFisher) were grown in M231 media supplemented with the smooth muscle growth supplement (Thermo Fisher and 20% FCS. For experiments involving TNF treatments, cells were grown in M231 media containing 2% serum (2%-M231). Both HUVEC and SMCs were used within 16 population doublings to maintain primary phenotype. THP1 monocytes were grown in RPMI media supplemented with 10% FCS, 1% pen strep and 1% glutamine. All cells used are certified as mycoplasma free at start of experiments. All cell catalogue numbers are listed in the Key Resource Table.

Cell transfection

Endothelial cells were plated for expression (6 well plates) or ATP assays (24 well plates) until 70-80% confluent. Media was removed and replaced with 0.1%-M200 for 30 minutes prior to transfection. siRNAs targeting the human PANX1 gene (Life Technologies Panx1 silencer select 4392420-s24427; 50-GUUUGUGGGAG GUAUCUGAtt-30), Cx43 (Life Technologies GJA1 silencer select 4392420-s5758; 50-GGCUAAUUACAGUGCAGAAAtt-30) or Control siRNAs (Life Technologies silencer select negative control 1, 4390843) or were transfected into ECs using Lipofectamine 3000. Media was changed after 24 hr and cells allowed to recover for 24 hr prior to treatment. siRNA knockdown for Panx1 was maximal at between 48-72 hr was confirmed by immunoblot and qRT-PCR.

Cell treatments

Prior to treatments, media was removed from cells and replaced with 0.1% -M200 for 24 hr. Media was then replaced with 0.1%-M200 containing 2.5 ng/mL TNF for up to 24 hr (as denoted per experiment). Where TNF dose responses were measured, the respective concentrations are

denoted in the text. Inhibition of ATP (Apyrase, 1 UN/mL) and P2 activation (Surmain, 100μM) were performed by 30 minutes pre-incubation prior to addition of TNF for a further 24 hr. Inhibition of protein synthesis was performed by pre-incubation with 25 μg/mL cyclohexamide.

Kinase inhibitors: Inhibitors of the IKK pathway SC514 (100 μM (Kishore et al., 2003)), and QNZ/EVP4593 (10 μM (Vigont et al., 2012)) and MAPK inhibitor SB203580 (10 μM (Adhikary et al., 2008)) were sourced from Selleck chemicals. All inhibitors were pre-incubated with cells for 3 hr prior to treatment with TNF for a further 24 hr.

RNA extraction RT-qPCR and RNA seq

Following treatments, media was removed, cells washed once in PBS, then 1mL of Trizol added prior harvesting by scraping. RNA was isolated using an RNA isolation kit (Aurum Total RNA isolation kit, #732-6830, BioRad) as per manufacturer protocol and cDNA synthesis performed using first strand synthesis kit (Thermo Fisher). Multiplex Taqman reactions were performed using 20ng of cDNA, Taqman primers (Thermo Fisher, see Key Resource Table) and Taqman gene expression mastermix (Thermo Fisher, #4369016). The internal control gene GAPDH was used for normalization and calculation of the delta CT values. All data are represented as delta-delta CT ($2^{-\Delta\Delta CT}$) to define fold change from control values. For RNA-seq, Total RNA was isolated using an RNeasy kit (Qiagen) with an RNA free DNase step and quantity assessed on an Agilent 2100 Bioanalyzer. For experiments, three technical replicates (HUVEC no treatment and HUVEC TNF 2.5 ng/mL 24 hr) were sequenced with ribodepletion protocols. After sequencing 50 M reads were sampled from each replicate library and results analyzed by Glasgow Polyomics. Data from RNA-Seq is available through EMBL-EBI ArrayExpress, accession number E-MTAB-8299.

Immunoblotting and membrane protein biotinylation

Following treatments, all cells were harvested in cold lysis containing PBS (pH 7.4) containing: NaCl (125 mM); EDTA (5 mM); sodium deoxycholate (1%); triton X-100 (0.5%); sodium orthovanadate (500 μM); AEBSF (10 μM) and protease inhibitor cocktail (1:100, Sigma). All isolations were performed at 4 °C, samples were dounce homogenized 30 times on ice, incubated with rotation for 30 mins at 4 °C and centrifuged at 14,000g for 5 minutes. Cleared lysates were used for immunoblot analysis. Proteins samples were quantified by BCA assay prior to loading and equal loading confirmed using β-tubulin and total protein assays. Membranes were developed using Licor secondary antibodies anti-rabbit-700/800 and anti-mouse-700/800 (1:10,000) and imaged on a Licor Odyssey scanner. Expression analysis was performed using

Image studio (Licor). Values were normalized to β -tubulin and changes calculated as a fold change compared to non-treated controls.

Cytokine array

Human cytokine array kit (R&D systems, proteome profiler XL ARY022) were used as per manufacturers protocols using 1mL of cleared culture media. Medias from 3 separate experiments under the same conditions were combined per reaction. Cytokine array membranes were developed using anti-streptavidin 800 on a Licor Odyssey scanner. Expression analysis was performed using Image studio (Licor). Values were normalized to the control spots on each blot and comparisons made to non-treated controls and expressed as a fold change from TNF control.

Luciferase assay for ATP release

ATP assays were performed as we have previously described (Lohman et al., 2015). Briefly, cultured EC were seeded in 24-well plates and grown to 70-80% confluency. Media was replaced with 0.1%-M200 media containing TNF (2.5 ng/mL) for 24 hr. On the day of the experiment cells were rinsed then incubated in 300 μ L of fresh 0.1%-M200 media for 30 min at 37 °C, then incubated with the ectonucleotidase inhibitor ARL 67156 (300 μ M, Tocris) for 30 min at 37 °C. Cells were then stimulated with recombinant human TNF (10 ng/mL) for 30 minutes. Following stimulation, 200 μ L of the cell supernatants were collected, placed into pre-chilled tubes, centrifuged at 10,000 xg for 5 min and 50 μ L of each sample was transferred to a white, opaque 96-well plate. ATP was measured using ATP bioluminescence assay reagents, CellTitre Glo 2.0 (Promega) or ATP Bioluminescence HSII kit (Roche). Using a FluoStar Omega luminometer, 50 μ L of luciferin:luciferase reagent (ATP bioluminescence assay kit HSII; Roche) was injected into each well and luminescence was recorded following a 5-s orbital mix. For CellTitre Glo 2.0, reagent was mixed 50:50 with cleared HUVEC media. ATP concentration in each sample were calculated from an ATP standard curve. Data are presented either as calculated concentration or as a % change in ATP release from baseline (unstimulated cells) and expressed as mean $\pm$ s.e.m. (N=5 independent experiments with triplicate measurements).

Flow cytometric analysis of intracellular calcium and monocyte adhesion

Monocyte adhesion assay: HUVECs were seeded on fibronectin coated plates and grown to 70% confluence. Cells were washed twice in warmed PBS and media changed for 0.1%-M200 for 24 hr. Media was changed for 0.1%-M200 with TNF (2.5ng/mL) for 24 hr. At the same time, human THP-1 monocytes were loaded with calcein-AM (0.1 μ M, Sigma) in RPMI for 30 mins. THP-1 cells were then centrifuged, and washed twice in PBS prior to being resuspended in 10% RPMI

media for 24 hr. After 24 hr, TNF was removed from HUVEC by washing once in 0.1%-M200 and cells incubated in fresh 0.1%-M200 for 30 minutes. During this time, calcein loaded THP-1 cells were counted and resuspended to a concentration of 5×10^5 cells/mL in 0.1%-M200. THP1 cells ($100 \mu\text{L}$, 5×10^4) were added to each well for 4 hr at 37°C . After 4 hr, the wells were washed gently two times with PBS to remove non-adherent cells. All remaining cells were then trypsinized and resuspended in 0.1%-M200 media and stored on ice for analysis by flow cytometry (BD FACScanto II). Gates for calcein stained THP1 and non-stained endothelial cells were defined and percentage of THP1 monocytes calculated from the total cells (endothelial cells and THP1 cells).

QUANTIFICATION AND STATISTICAL ANALYSIS

1-way or 2-way ANOVA followed by Tukey or Dunnett post-test were used for comparisons between 3 groups and T-test used for comparisons of 2 treatment groups. A minimum of $N=3$ were used for all statistical analysis. In all analysis a P value of 0.05 is significant, * is $P<0.05$, *** is $P<0.01$, *** is $P<0.001$ **** is $P<0.0001$

SUPPLEMENTAL INFORMATION

Supplemental information can be found online

FUNDING

Support for this work came from National Institute of Health grants HL120840 (B.E.I.), HL137112 (B.E.I. and M.K.), from the China Scholarship Council (Y.Y.), an American Heart Association Career Development Award (19CDA34630036, S.R.J.), Lord Kelvin Adam Smith Research Fellowship from (University of Glasgow S.R.J.) and Wellcome Trust ISSF Funding (University of Glasgow S.R.J.).

AUTHOR CONTRIBUTION

S.R.J., B.E.I. and M.K. conceived this study conceptualized and provided financial backing. S.R.J. and Y.Y. designed and executed the majority of the experiments. L.D., A.K.B., E.M., and J.M. performed extensive cell culture and immunoblotting. A.M., I.D. designed and performed RNA analysis for RNA-seq. M.M. performed RNA-seq and generation of ingenuity pathway data analysis. Y.Y. wrote the manuscript with input from X.H.S., M.K., B.E.I. and S.R.J.

ACKNOWLEDGEMENTS

We thank Anita Impagliazzo for illustration. The UVA School of Medicine Flow Cytometry Facility was used for flow cytometric analysis. The University of Glasgow Polyomics core was used for RNA-seq and data interpretation and analysis. We thank Dr Graham Hamilton, Glasgow Polyomics for his input in experimental design and analysis of RNA-seq data.

CONFLICT OF INTEREST

The authors have no conflicts to disclose.

FIGURE LEGENDS

Figure 1. TNF transcriptional regulation of Panx1 through the NF κ B pathway promotes protein synthesis and plasma membrane trafficking

(A) Taqman qRT-PCR of RNA extracted from HUVECs treated with TNF (2.5 ng/mL) for 5 and 24 hr. The mean of Panx1 expression was normalized to control and calculated to $2^{-\Delta\Delta CT}$. Each error bar was performed in triplicates in addition to the technical triplicates.

(B) Representative immunoblots of pannexin 1 (Panx1) and Connexin 43 (Cx43) in HUVECs pretreated with cycloheximide (CBX) 30 minutes and subsequent TNF (2.5 ng/mL) treatment for 24 hr. Quantification of Panx1 expression was normalized to β -tubulin (n=3).

(C) Upper panel schematic of HUVECs treatment approach to assess Panx1 protein lifecycle. Black arrowhead marks the time TNF was added and removed. The blue scale marks cells maintained in 0.1%-M200 (no TNF) collected each 24 hr after TNF removal. Lower panel, representative immunoblots of Panx1 and β -tubulin expression and quantification of Panx1 expression under these treatment conditions (n=3).

(D) Representative immunoblots of HUVECs treated with TNF (2.5 ng/mL) for time course 5 minutes, 5 and 24 hr, and subsequent immunoprecipitation of cell surface biotinylated membrane proteins. Plasma membrane localized Panx1 expression was normalized to biotin-labeled total protein (n=5).

(E) RNA sequence performed on HUVECs treated with TNF (2.5 ng/mL) for 24 hr. The expression of five genes in NF κ B family are shown with each bar represents mean $\pm$ SD for triplicates (n=3).

(F) Represent immunoblots of TNF (2.5 ng/mL) induced HUVECs in presence or absence of inhibitors: inhibitor of nuclear factor kappa-B kinase-2 (IKK2) 100 μ M SC514 (n=5) or NF κ B inhibitor 10 μ M QNZ (n=3) for 24 hr.

Statistical analyses were performed by one-way or two-way ANOVA with either Dunnett or Tukey's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.001.

Figure 2. Panx1 controls transcription of selective inflammatory cytokines

(A) qRT-PCR analysis of Panx1 in HUVECs transfected with control siRNA (siControl) or siRNA Panx1 for 48 hr followed with 24 hr TNF (2.5 ng/mL) treatment. Each reaction was performed in triplicates in addition to the technical triplicates (n=3).

(B) Representative immunoblot of Panx1 in HUVECs transfected with siControl or siRNA Panx1 for 48 hr followed 24 hr TNF (2.5 ng/mL) treatment. Panx1 expression was normalized to β -tubulin and expressed as fold change (n=4).

(C) Cell media collected from HUVECs transfected with siControl or siRNA Panx1 for 48 hr followed with 24 hr TNF (2.5 ng/mL) treatment were incubated with human XL cytokine array (n=2). Representative cytokine spot duplicates for each group were shown with the relative mean measurement.

qRT-PCR analysis the expression of IL-1 β and CXCL10 (D), IL8 and CCL2 (E), and MIF and CD147 (F) in HUVECs transfected with control siRNA (siControl) or siRNA Panx1 for 48 hr followed with 24 hr TNF (2.5 ng/mL) treatment. Cytokines were normalized to control and calculated to $2^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

Statistical analyses were performed by one-way or two-way ANOVA with either Dunnett or Tukey's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.001.

Figure 3. ATP release through Panx1 channel opening is not associated with IL-1 β regulation

(A) ATP release measured and quantified as fold change from control (0 ng/mL TNF) to HUVECs pretreated with TNF (0, 2.5, 25, 50, 100 ng/mL) for 24 hr then stimulated with TNF (10 ng/mL) stimulated for 5 minutes (n=3).

(B) ATP release measured and quantified as fold change from control (siControl or siPanx1, 0 ng/mL TNF) with 24 hr incubation of TNF (2.5 ng/ml) in response to 5 minutes TNF (10 ng/mL) stimulation (n=5).

(C) Calculated mean extracellular ATP concentration from 24 hr TNF pretreatment HUVECs in response to TNF (10 ng/mL) for 5 minutes (n=6).

(D) qRT-PCR analysis of IL-1 β expression in HUVECs applied to a dose response for exogenous ATPys (10, 100 nM, 1 and 100 μ M), a stabilized ATP substrate to assess the potential effect on IL-1 β upregulation (n=3). Data were normalized to control and calculated to $2^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

(E) qRT-PCR analysis of IL-1 β in HUVECs treated with ATPys (100 μ M), in the presence of suramin to (100 μ M) to block P2X receptors (n=3). Data were normalized to control and calculated to 2 $^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

(F) qRT-PCR analysis of Panx1 and IL-1 β in HUVECs pretreated with Apyrase (1UN/mL), to degrade extracellular ATP, then with TNF (2.5 ng/mL) for 24 hr (n=3). Data were normalized to control and calculated to 2 $^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

(G) qRT-PCR analysis of Panx1 and IL-1 β in HUVECs pretreated with Suramin (100 μ M), to block P2X receptor activity, then with TNF (2.5 ng/mL) for 24 hr (n=3). Data were normalized to control and calculated to 2 $^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

Statistical analyses were performed by one-way or two-way ANOVA with either Dunnett or Tukey's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.001.

Figure 4. Panx1 facilitates increased intracellular Ca²⁺ associated with inflammatory regulation

(A) Represent [Ca²⁺]_i traces evoked in HUVECs treated with TNF (2.5 ng/mL) for 24 hr (red) compared to in control (blue) and 5 hr treatment (magenta). Cells were loaded with Fluo-4 AM (1 μ M) and analyzed on BD FACScanto II flow cytometry. Graphs of median Fluo4 fluorescence of [Ca²⁺]_i were quantified for average individual fluorescence compared with control as indicated (n=3).

(B) Flow cytometric measurement of median [Ca²⁺]_i in HUVEC in calcium free Krebs solution siRNA treatments (siControl, siPanx1) transfected cells treated with TNF (2.5 ng/mL) for 24 hr (n=3).

(C) Flow cytometric measurement of median [Ca²⁺]_i in HUVEC treated with TNF (2.5 ng/mL) for 24 hr in presence of a chelator of calcium EGTA-AM (n=3).

(D) qRT-PCR analysis of IL-1 β expression in HUVECs treated with TNF (2.5 ng/mL) for 24 hr in the presence of a chelator of calcium EGTA-AM (n=3). Data were normalized to control and calculated to 2 $^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

(E) Flow cytometric measurement of median $[Ca^{2+}]_i$ in HUVEC pretreated with PxIL2P peptide followed by TNF (2.5 ng/mL) treatment for 24 hr (n=3).

(F) qRT-PCR analysis of IL-1 β expression in HUVECs pretreated with Panx1 IL2 peptide followed by TNF (2.5 ng/mL) treatment for 24 hr. Data were normalized to control and calculated to $2^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

(G) Flow cytometric measurement of median $[Ca^{2+}]_i$ in HUVECs transfected with siPanx1 followed by TNF (2.5 ng/mL) stimulation (n=3).

(H) Flow cytometric measurement of median $[Ca^{2+}]_i$ in HUVECs treated with TNF for 24 hr as per experimental set up illustrated in Figure 1C schematic.

(I) qRT-PCR analysis of IL-1 β expression in HUVECs treated with TNF for 24 hr, then washed out for 8 days, as per experimental set up illustrated in Figure 1C schematic. Data were normalized to control and calculated to $2^{-\Delta\Delta CT}$, then expressed as fold change. Each group was performed in triplicates in addition to the technical triplicates (n=3).

(J) Represent immunoblots of HUVECs treated with TNF (2.5 ng/mL) for 24 hr post-transfected with siRNA (siControl or siPanx1) for 48 hr. β -tubulin was used as a loading control. The relative changes of P-p65 and p65 expression were calculated in comparison with siControl no treatment (n=3).

(K) Represent immunoblots of HUVECs pretreated with PxIL2P peptide followed with TNF (2.5 ng/mL) stimulation for 24 hr. β -tubulin was used as a loading control. The relative changes of P-p65 and p65 expression were calculated in comparison with control no treatment (n=3).

Statistical analyses were performed by one-way or two-way ANOVA with either Dunnett or Tukey's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.001.

FIGURES:

Figure 1. TNF transcriptional regulation of Panx1 through the NFκβ pathway promotes protein synthesis and plasma membrane trafficking

Figure 2. Panx1 controls transcription of selective inflammatory cytokines

Figure 3: ATP release through Panx1 channel opening is not associated with IL-1β regulation

Figure 4: Panx1 facilitates increased intracellular Ca^{2+} associated with inflammatory regulation

SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1: TNF increase of Panx1 in EC is not associated with activation of MAPK pathways or cell death

Protein lysates were isolated from HUVECs treated with a series of concentrations ranging from 2.5 ng/mL to 100 ng/mL TNF for either 5 or 24 hr. Non-treated cells were used as a control.

Representative western blot analysis of Panx1 in HUVECs in response to doses of TNF for 5 hr (A) or 24 hr (B). In both A and B, Panx1 was analyzed as both bands (total Panx1) or as separate glycosylated species, Gly 2-Panx1 (upper band) or Gly 0/1-Panx1 (lower bands). Panx1 expression was normalized to β -tubulin and expressed as fold change from untreated (n=3).

(C) Representative western blots of Connexin 43 (Cx43) in response to doses of TNF for 24 hr. Cx43 expression was normalized to β -tubulin and expressed as fold change from untreated (n=3).

(D) Representative western blot of Panx1 in SMC treated with 2.5 ng/mL TNF for 5 and 24 hr. Panx1 expression was normalized to β -tubulin and expressed as fold change from untreated (n=3).

(E) Intracellular ATP levels for HUVECs treated with doses of TNF (0.25, 1, 2.5, 10 and 25 ng/mL) for 24 hr or exposed under UV light for 10 minutes. Cell viability was expressed as fold change ATP luminescence in comparison to untreated cells (n=3).

(F) Representative western blots for caspase 3 in HUVECs treated with a series of concentrations ranging from 2.5 ng/mL to 100 ng/mL TNF for 24 hr. Pro-caspase expression was normalized to β -tubulin and expressed as fold change from untreated cells (n=3).

(G) Represent microscope images of HUVECs treated with a series of concentrations ranging from 2.5 ng/mL to 100 ng/mL TNF for 24 hr, show no evidence of cell death e.g. lower cell numbers or membrane blebbing.

(H) RNA-Seq results of HUVECs treated with TNF (2.5 ng/mL). The expression of thirteen genes in MAPK family are shown with each bar represents mean $\pm$ SD for triplicates (n=3).

(I) Representative western blot of TNF (2.5 ng/mL)-induced HUVECs in presence or absence of inhibitors: inhibitor of nuclear factor kappa-B kinase-2 (IKK2) 100 μ M SC514 (n=5) or MAPK inhibitor 10 μ M SB203580 (n=3).

In A-E, Statistical analyses were performed by one-way ANOVA with Dunnett's' multiple comparison test, * indicates comparison to not treated Total-Panx1, \$ indicates comparison to not treated Gly1/0-Panx1, F indicates comparison to not treated Gly2-Panx1. */\$P<0.05, \$\$/F\$P<0.01,

****P<0.001. In I, Statistical analyses were performed by two-way ANOVA with Tukey's multiple comparison test, ***P<0.001, ****P<0.001.

Supplemental Figure 2: Cytokine array of HUVEC treated with TNF

Representative human cytokine array membranes (siControl and siPax1 with or without TNF) show 102 biomarkers spotted in duplicate and arranged in a grid format. HUVECs transfected with control siRNA (siControl) or Pax1 (siPax1) for 48 hr followed with TNF (2.5 ng/mL) treatment for 24 hr. Media from 3 technical replicates were pooled and incubated with array membranes. Images were visualized using LICOR Odyssey imaging system. Differences between TNF-treated siControl and siPax1 were measured by LICOR in 2 independent experiments. The fluorescence intensity of cytokines were normalized to reference values on blots and expressed as the percentage of siControl TNF in the histogram (n=2).

Supplemental Figure 3: Pax1 regulates TNF associated leukocyte binding

Representative histograms from flow cytometry of calcein loaded leukocyte binding with HUVEC transfected with either control siRNA (siControl) or Pax1 siRNA (siPax1) for 48 hours prior to TNF (2.5 ng/mL) stimulation for 24 hr.

(A) Representative histograms highlighting percentage calcein-THP1 cells bound to HUVECs in each group.

(B) Percentage of leukocyte binding in triplicates. Statistical analyses were performed by two-way ANOVA with Tukey's multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.001.

(B) Western blot analysis of Pax1 in human monocytes (THP1) treated with 2.5ng/mL TNF for 24 hr. Total protein expression values of Pax1 were normalized to β -tubulin and expressed as fold change (n=3). Statistical analyses were performed by Student's test.

Supplemental Figure 1: TNF increase of Panx1 in EC is not associated with activation of MAPK pathways or cell death

1

2

Supplemental Figure 2: Cytokine Array of HUVEC treated with TNF

Supplemental Figure 3: Panx1 regulates TNF-associated monocyte binding.